A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia - Kinon, B J; Zhang, L; Millen, B AHBBI Study Group (J Clin Psychopharmacol, 2011)
et al.